Company intelligence / Profile preview

The 221b Foundation

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Nonprofit foundation created by Sherlock Biosciences to license and disseminate SHERLOCK CRISPR diagnostic IP globally for COVID-19 testing, enabling partners to manufacture and distribute high-throughput and point-of-care SARS-CoV-2 diagnostics while using proceeds to support diversity in STEM.[1][2][4][7]

Therapeutic areas: Infectious Diseases
Modalities: CRISPR-based diagnosticsDevice
Industry: Molecular Diagnostics

Partnerships

ALBOT Technologies[1]Cooper International / Cooper Pharma[1][2]LogicInk[1][4]Rokline[1]United PPE / United PPE America[1][2]binx health[1]Coalition partners for Nepal COVID-19 testing (multiple organizations)[7]

Beyond the preview

Go deeper on The 221b Foundation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on The 221b Foundation.

Explore the full profile